Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of shortened infusion times for oncologic monoclonal antibody immunotherapies
NL-OMON51857Not yet recruiting
- Sponsor
- Isala
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab, pembrolizumab, ipilimumab, durvalumab, atezolizumab and 2 more in cancer, bronchial carcinoma, melanoma and 1 more (2 cohorts), sponsored by Isala. Primary endpoints: Incidence of infusion-related or hypersensitivity reactions, Grade of infusion-related reactions and 2 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
03
Conditions
cancerbronchial carcinomamelanomabreast cancer
Beyond the preview
Go deeper on NL-OMON51857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51857.